Clinical Trials on HCMV Reactivation or HCMV End-Organ Disease

Total 71400 results

AiCuris Anti-infective Cures AG
Quintiles, Inc.

Completed

Safety and Efficacy Study of a New Antiviral Drug to Prevent Cytomegalovirus Reactivation in Bone Marrow Transplanted Patients

HCMV Reactivation or HCMV End-Organ Disease

United States, Germany
Imperial College London

Withdrawn

Autologous Cytomegalovirus (CMV) Specific CD8+ T Cells as Treatment for CMV Reactivation

Allogeneic Stem Cell Transplantation | CMV Reactivation | Autologous CMV Specific CD8+ T Cells

United Kingdom
Siriraj Hospital

Not yet recruiting

The Comparison the CMV Infection and Reactivation After Allogeneic Hematopoietic Stem Cell Transplantation Between Standard Regimen, Methotrexate Plus Cyclosporin A, and Post-transplant Cyclophosphamide-based Regimen (CMV)

CMV Infection or Reactivation After Allogenic HSCT
Hebei Yanda Ludaopei Hospital
China Immunotech (Beijing) Biotechnology Co., Ltd.

Completed

CMV-TCR-T Cells for CM Virus Infection After HSCT

CMV Infection or Reactivation After Allogenic HSCT

China
Assistance Publique Hopitaux De Marseille

Unknown

Evaluation of Methods for Diagnosis of Cytomegalovirus Pneumonia in Mechanically Ventilated Patient

CMV Reactivation Diagnosis in ICU Patient

France
St George's, University of London
St George's University Hospitals NHS Foundation Trust

Active, not recruiting

Cytomegalovirus Shedding Characteristics in Pregnant Women (cCHIPS)

CMV | Congenital Cmv | Maternal Infections Affecting Fetus or Newborn | Shedding Virus

United Kingdom
Institute of Hematology & Blood Diseases Hospital

Not yet recruiting

Letermovir for Primary Prophylaxis of Cytomegalovirus Infection After R+HID-HSCT

The Incidence of Peripheral Blood CMV Activation and Confirmed Clinically Significant CMV Infection Within 24 Weeks After Transplantation
Institute of Hematology & Blood Diseases Hospital

Not yet recruiting

Secondary Prophylaxis of CMV Infection Using Letermovir After HID-HSCT

To Evaluate the Efficacy and Safety of Secondary Prophylaxis of CMV Reactivation
Merck Sharp & Dohme LLC

Completed

Letermovir (MK-8228) Versus Placebo in the Prevention of Clinically-Significant Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients (MK-8228-001)

Prevention of CMV Infection or Disease
Hadassah Medical Organization

Withdrawn

Adoptive Immunotherapy for CMV Disease

CMV Disease

Israel
Novartis Pharmaceuticals

Withdrawn

A Study to Evaluate CSJ148 in Pregnant Women With Primary HCMV Infection

HCMV Infection
Merck Sharp & Dohme LLC

Completed

Letermovir Versus Valganciclovir to Prevent Human Cytomegalovirus Disease in Kidney Transplant Recipients (MK-8228-002)

CMV Disease

United States, Argentina, Australia, Austria, Belgium, Canada, Colombia, France, Germany, Hungary, Italy, Mexico, New Zealand, Poland, Spain, United Kingdom
Merck Sharp & Dohme LLC

Completed

V160 2-Dose and 3-Dose Regimens in Healthy Cytomegalovirus (CMV) Seronegative Females (V160-002)

Cytomegalovirus (CMV) Infections

United States, Australia, Canada, Finland, Israel, Russian Federation, Spain
University of Nebraska

Completed

Cytomegalovirus Testing and Intervention Protocol for Newborn Nursery and Newborn Intensive Care Unit

Congenital CMV Infection

United States
Atara Biotherapeutics

No longer available

Expanded Access Protocol of ATA230 (Third-Party Donor-Derived CMV-CTLs) for the Treatment of CMV Viremia or Disease

CMV Viremia | CMV Disease
University of Alabama at Birmingham

Recruiting

Cytomegalovirus (CMV) Vaccines: Reinfection and Antigenic Variation (CMV)

Cmv Congenital | CMV Viremia

Brazil
The Republican Research and Practical Center for...
Belarusian State Medical University

Enrolling by invitation

Clinical and Immunological Features of the CMV Infection Atypical Course in Immunocompetent Individuals

CMV

Belarus
New York Medical College

Recruiting

CMV CTLs in Neonates With CMV Infection

Congenital Cytomegaloviral (CMV) Disease

United States
Hospital Israelita Albert Einstein

Recruiting

Expansion of Virus-Specific Lymphocytes for Cell Therapy

CMV | CMV Viremia

Brazil
Gilead Sciences

Completed

Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Treatment-Naive and Treatment-Experienced Subjects With Chronic Genotype 4 or 5 HCV Infection

Chronic Genotype 4 HCV | Chronic Genotype 5 HCV

France
Hookipa Biotech GmbH

Completed

A Study of CMV Vaccine (HB-101) in Kidney Transplant Patients

Kidney Transplantation | Cytomegalovirus (CMV) Infection

United States, Denmark, Norway, United Kingdom, Germany, France
St George's, University of London
European Society for Paediatric Infectious Diseases

Recruiting

Observational Study of the Management of Infants With Congenital CMV (cCMVnet)

Congenital Cmv

United Kingdom
AlloVir

Completed

Most Closely Human Leukocyte Antigen (HLA)-Matched CMV-specific T Lymphocytes (Viralym-C)

CMV Infections

United States
Valme University Hospital
Boehringer Ingelheim

Unknown

Influence of Nevirapine on HCV Viral Load (HELICON)

HCV Infection. | HCV Viral Load.

Spain
Astellas Pharma Global Development, Inc.
Vical

Completed

A Study to Evaluate the Efficacy and Safety of a Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seronegative Kidney Transplant Recipients Receiving an Organ From a CMV-Seropositive Donor

Kidney Transplantation Cytomegalovirus (CMV) Negative Recipients

United States, Australia, Canada, France, Germany, Spain
Albert Park
Genentech, Inc.; National Institute on Deafness and Other Communication Disorders...

Active, not recruiting

Randomized Controlled Trial of Valganciclovir for Cytomegalovirus Infected Hearing Impaired Infants (ValEAR)

Cmv Congenital | CMV | Congenital Cmv | SNHL | Sensorineural Hearing Loss

United States
Johns Hopkins University
National Institute of Allergy and Infectious Diseases (NIAID)

Recruiting

Prophylaxis With Direct-acting Antivirals for Kidney Transplantation From HCV-Infected Donors to Uninfected Recipients (PREVENT-HCV)

HCV

United States
Tibotec Pharmaceuticals, Ireland

Completed

TMC435350-TiDP16-C109: A Safety Study for TMC435350 in an Oral Solution Containing Either 100, 200 or 400 mg Equivalent of TMC435350 or Placebo in Healthy Japanese Male Volunteers

HCV
Institute of HIV Research and Innovation Foundation...
amfAR, The Foundation for AIDS Research

Recruiting

The South-East Asian Transgender Health Cohort (SEATrans)

HIV | HCV | STIs

Philippines, Thailand, Vietnam
St. Jude Children's Research Hospital
Oxford Immunotec

Terminated

Evaluating the Clinical Utility of the T-SPOT.CMV Assay for the Prediction of CMV Reactivation Among Pediatric Patients Undergoing Hematopoietic Cell Transplant

CMV

United States
Tel-Aviv Sourasky Medical Center
Merck Sharp & Dohme LLC

Unknown

the Effect of Grazoprevir/Elbasvir and TACE vs. TACE Alone in Prolonging Survival of Patients With Non-resectable HCV Associated HCC. (ZEPATIER)

HCV, HCC
Gilead Sciences

Completed

GS-5885, GS-9451, Tegobuvir and Ribavirin (RBV) in Interferon Ineligible or Intolerant Subjects With Chronic Genotype 1a or 1b Hepatitis C Virus (HCV) Infection

Chronic Genotype 1a or 1b HCV Infection

United States, Canada, Puerto Rico
MTI University

Unknown

The Renal Safety in Patients With Chronic HCV Undergoing Sofosbuvir Containing Antiviral Therapy

Egyptian Patients, HCV Treatment, Kidney Function

Egypt
National Institutes of Health Clinical Center (CC)
Bristol-Myers Squibb; National Institute of Allergy and Infectious Diseases...

Completed

Safety, Tolerability, and Efficacy of Asunaprevir and Daclatasvir in Subjects Coinfected With HIV-HCV

HIV-HCV

United States
Beijing Chao Yang Hospital

Unknown

The Link Between Human Cytomegalovirus (HCMV) and Hypertension

Hypertension | HCMV Infection

China
Kirby Institute
Australasian Society for HIV Viral Hepatitis and Sexual Health Medicine (ASHM) and other collaborators

Recruiting

National Prisons Hepatitis Education Project: Research Evaluation (HepPEd)

HCV

Australia
Assiut University

Unknown

Safety of Sofosbuvir ,Daclatasvir in HCV Patients and RAVS in Resistent and Relapsed Cases (RAVs)

HCV
Institute of HIV Research and Innovation Foundation...

Recruiting

KP-Led Same Day HCV Test and Treat Study (479/65)

HCV, HIV

Thailand
Assistance Publique Hopitaux De Marseille

Unknown

Analysis of the Impact of HCV Treatment by Last Generation Direct Antiviral Agents (DAA) on Antiviral Immunity and HIV DNA Reservoir in Coinfected HIV-HCV Patients (HCURE)

HIV Associated HCV

France
Memorial Sloan Kettering Cancer Center
Merck Sharp & Dohme LLC

Recruiting

A Study of the Drug Letermovir (LTV) as Prevention for Recurrent of Cytomegalovirus (CMV) Infection

CMV | CMV Infection | Hematopoietic Cell Transplant

United States
Astellas Pharma Global Development, Inc.

Completed

A Study to Evaluate a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT) (HELIOS)

Cytomegalovirus (CMV)-Positive Recipients | Allogeneic, Hematopoietic Cell Transplant (HCT)

Japan, Korea, Republic of, United States, Canada, Australia, Belgium, France, Germany, Spain, Sweden, Taiwan
Beckman Coulter, Inc.

Completed

Access Anti-HCV Assay European Union (EU) Clinical Trial Protocol (HCV-EU-10-18)

HCV

France
Chimerix

Completed

A Study of the Safety and Efficacy of CMX001 for the Prevention of CMV Infection in CMV-seropositive HCT Recipients

CMV

United States, Belgium, Canada
Assistance Publique - Hôpitaux de Paris
Gilead Sciences

Terminated

HCV, HBV, HIV Testing During Consultation With Anesthesiologist (SAHARA)

Hiv | HBV | HCV

France
Nanfang Hospital, Southern Medical University

Recruiting

Prospective Cohort Study of Complications and Outcomes in Cirrhosis

Decompensated Cirrhosis | Overt Hepatic Encephalopathy | CMV Reactivation

China
Chinese PLA General Hospital

Recruiting

CMV-TCR-T Cells for CMV Infection After Allogenic HSCT

CMV Infection After Allogenic HSCT

China
University Hospital, Clermont-Ferrand
Merck Sharp & Dohme LLC

Completed

Study to Investigate the Efficacy of Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in Treatment-Naïve, HCV GT1b-Infected Patients, With Non-severe Fibrosis (STREAGER)

Chronic HCV Infection

France
Azienda Ospedaliera Universitaria Policlinico Paolo...

Completed

Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in G1b Treatment-Naïve, HCV-Infected Patients (EGG-18)

Chronic HCV Hepatitis

Italy
Radboud University Medical Center

Withdrawn

Bioequivalence Study of Crushed Sofosbuvir/Velpatasvir Compared to the Whole Tablet (CRUSADE-1)

HCV

Netherlands, Germany
University Hospital, Limoges

Completed

A French Cohort of Transplant Recipients With CMV Infection : Risk Factors for Antiviral Resistance in the Prophylaxis Era. (ORPHAVIC)

Transplant Recipients With CMV Infection

France

Clinical Trials on HCMV Reactivation or HCMV End-Organ Disease

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mauritius

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations